Common Contracts
262 similar Underwriting Agreement contracts by SONDORS Inc., Verve Therapeutics, Inc., ProFrac Holding Corp., others
Metagenomi, Inc. [•] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 5th, 2024 • Metagenomi, Inc. • Biological products, (no disgnostic substances) • New York
Metagenomi, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”.
UNDERWRITING AGREEMENT DYNE THERAPEUTICS, INC. 17,150,000 Shares of Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • January 5th, 2024 • Dyne Therapeutics, Inc. • Pharmaceutical preparations • New York
Dyne Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 17,150,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 2,572,500 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT VERVE THERAPEUTICS, INC. 12,500,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • November 29th, 2023 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
Verve Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 12,500,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,875,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
WAYSTAR HOLDING CORP. [ · ] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • November 15th, 2023 • Waystar Holding Corp. • Services-computer integrated systems design • New York
Waystar Holding Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ · ] shares (the “Underwritten Shares”) of common stock, par value $0.01 per share, of the Company (the “Common Stock”) and, at the option of the Underwriters, up to an additional [ · ] shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
BIRKENSTOCK HOLDING PLC [ • ] Ordinary Shares Underwriting AgreementUnderwriting Agreement • October 2nd, 2023 • Birkenstock Holding LTD • Footwear, (no rubber) • New York
Birkenstock Holding plc, a Jersey public limited company (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ • ] ordinary shares of the Company, and BK LC Lux MidCo S.à r.l., a société à responsabilité limitée, incorporated and existing under the laws of the Grand Duchy of Luxembourg, registered with the Luxembourg Trade and Companies’ Register under number B252140, having its registered office at 40 avenue Monterey L-2163, Grand Duchy of Luxembourg, being the sole shareholder of the Company (the “Selling Shareholder”), proposes to sell to the several Underwriters an aggregate of [ • ] ordinary shares of the Company (collectively, the “Underwritten Shares”). In addition, the Selling Shareholder proposes to sell, at the option of the Underwriters, up to an additional [ • ] ordinary shares of the Company (collectively, the “Option Sha
VITAL ENERGY, INC. 2,750,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 19th, 2023 • Vital Energy, Inc. • Crude petroleum & natural gas • New York
UNDERWRITING AGREEMENT RayzeBio, Inc. [●] Shares of Common StockUnderwriting Agreement • September 11th, 2023 • RayzeBio, Inc. • Pharmaceutical preparations • New York
RayzeBio, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, and certain stockholders of the Company named in Schedule 2 hereto (the “Selling Stockholders”) propose to sell to the several Underwriters an aggregate of [●] shares of the Company (collectively, the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Akoya Biosciences, Inc. 8,700,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 12th, 2023 • Akoya Biosciences, Inc. • Laboratory analytical instruments • New York
Akoya Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 8,700,000 shares of common stock, par value $0.00001 per share, of the Company (the “Underwritten Shares” and, at the option of the Underwriters, up to an additional 1,305,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
ImmunoGen, Inc. 26,000,000 Shares of Common Stock, par value $.01 per share Underwriting AgreementUnderwriting Agreement • May 5th, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 26,000,000 shares (the “Firm Shares”) of common stock, par value $.01 per share, of the Company (the “Common Stock”) and, at the option of the Underwriters, up to an additional 3,900,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
InflaRx N.V. 9,411,765 Ordinary Shares Underwriting AgreementUnderwriting Agreement • April 13th, 2023 • InflaRx N.V. • Pharmaceutical preparations • New York
InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law, (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 9,411,765 ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,411,764 Ordinary Shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are referred to herein as the “Securities”. The Ordinary Shares to be outstanding after giving effect to the sale of the Securities are referred to herein as the “Stock”. To the extent there are no additional Underwriters listed on Schedule 1 other than you, the term “Representative” as used herein shall mean you, as Underwriter, and the terms “Representative” and “Underwriter” shall mean either the singula
ORMAT TECHNOLOGIES, INC. 3,600,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • March 16th, 2023 • Ormat Technologies, Inc. • Electric services • New York
Ormat Technologies, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 3,600,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 540,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.” To the extent that there shall be a sole Underwriter named in Schedule 1 hereto, all references to the Representatives and to the Underwriters shall be deemed to refer only to such sole Underwriter, and all corresponding changes in this Agreement from plural to singular shall be de
UNDERWRITING AGREEMENT SONDORS INC. [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 7th, 2023 • SONDORS Inc. • Motorcycles, bicycles & parts • New York
SONDORS Inc., a Delaware corporation (the “Company”), proposes to issue and sell to A.G.P./Alliance Global Partners (the “Underwriter”) an aggregate of [●] shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriter, up to an additional [●] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT SONDORS INC. [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 24th, 2023 • SONDORS Inc. • Motorcycles, bicycles & parts • New York
SONDORS Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
6,500,000 Shares of Common Stock par value $0.01 975,000 Option Shares Novavax, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 19th, 2022 • Novavax Inc • Biological products, (no disgnostic substances) • New York
Novavax, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC are acting as representatives (the “Representatives”), an aggregate of 6,500,000 shares of common stock, $0.01 par value per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 975,000 shares of common stock, $0.01 par value per share, of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock, $0.01 par value per share, of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT SONDORS INC. [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • December 1st, 2022 • SONDORS Inc. • Motorcycles, bicycles & parts • New York
SONDORS Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of [●] shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Surgery Partners, Inc. Shares of Common Stock Underwriting AgreementUnderwriting Agreement • November 22nd, 2022 • Surgery Partners, Inc. • Services-general medical & surgical hospitals, nec • New York
Surgery Partners, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 23,469,388 shares of common stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 3,520,408 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT SILK ROAD MEDICAL, INC. 2,325,582 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 21st, 2022 • Silk Road Medical Inc • Surgical & medical instruments & apparatus • New York
Silk Road Medical, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 2,325,582 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 348,837 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Prime Medicine, Inc. [—] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 23rd, 2022 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Prime Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [l] shares of common stock, par value $0.00001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [l] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 11,627,907 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 14th, 2022 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,627,907 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,744,186 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
GRID DYNAMICS HOLDINGS, INC. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • September 9th, 2022 • Grid Dynamics Holdings, Inc. • Services-prepackaged software • New York
Grid Dynamics Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 5,714,286 shares of Common Stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 857,142 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
UNDERWRITING AGREEMENT VERVE THERAPEUTICS, INC. 8,333,334 Shares of Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • July 21st, 2022 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
Verve Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 8,333,334 shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,250,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
CONSENSUS CLOUD SOLUTIONS, INC. [ ] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 7th, 2022 • Consensus Cloud Solutions, Inc. • Services-prepackaged software • New York
Certain stockholders named in Schedule 2 hereto (the “Selling Stockholders”) of Consensus Cloud Solutions, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ ] shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”), and, at the option of the Underwriters, up to an additional [ ] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT ProFrac Holding Corp. 16,000,000 Shares of Class A Common Stock Underwriting AgreementUnderwriting Agreement • May 18th, 2022 • ProFrac Holding Corp. • Oil & gas field services, nec • New York
ProFrac Holding Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 16,000,000 shares of Class A common stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 2,400,000 shares of Class A common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Class A common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT ProFrac Holding Corp. Shares of Class A Common Stock Underwriting AgreementUnderwriting Agreement • November 30th, 2021 • ProFrac Holding Corp. • Oil & gas field services, nec • New York
UNDERWRITING AGREEMENT SPORTRADAR GROUP AG Shares of Class A Ordinary Shares Underwriting AgreementUnderwriting Agreement • September 7th, 2021 • Sportradar Group AG • Services-computer programming, data processing, etc. • New York
Sportradar Group AG, a Swiss corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of shares of Class A ordinary shares, each having a nominal value of CHF 0.10, of the Company (the “Underwritten Shares”). In addition, the stockholder of the Company named in Schedule 2 hereto (the “Selling Stockholder”) proposes to issue and sell, at the option of the Underwriters, up to an additional shares of Class A ordinary shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The Class A ordinary shares of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
SVB FINANCIAL GROUP Common Stock Underwriting Agreement August 9, 2021Underwriting Agreement • August 12th, 2021 • SVB Financial Group • State commercial banks • New York
SVB Financial Group, a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 2,227,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 334,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Nuvalent, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • July 26th, 2021 • Nuvalent, Inc. • Pharmaceutical preparations • New York
Nuvalent, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of [●] shares (the “Underwritten Shares”) of common stock, par value $0.0001 per share (the “Class A common stock”), of the Company or, to the extent shares are purchased by entities affiliated with Deerfield Healthcare Innovations Fund, L.P. or Deerfield Private Design Fund IV, L.P., Class B common stock, $0.001 par value per share (the “Class B common stock” and, together with the Class A common stock, the “Common Stock”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to
SOPHiA GENETICS SA [●] Ordinary Shares Underwriting AgreementUnderwriting Agreement • July 19th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
SOPHiA GENETICS SA, a corporation (société anonyme) incorporated under the laws of Switzerland (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] ordinary shares, par value CHF 0.05 per share (the “Ordinary Shares”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to [●] additional Ordinary Shares (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.”
DYNACURE S.A. [●] American Depositary Shares Representing [●] Ordinary Shares Underwriting AgreementUnderwriting Agreement • July 12th, 2021 • Dynacure S.A. • Pharmaceutical preparations • New York
The Offered ADSs are to be issued pursuant to a deposit agreement (the “Deposit Agreement”) dated as of [●], 2021 by and among the Company, Citibank, N.A., as Depositary (the “Depositary”) and all holders and beneficial owners from time to time of the Offered ADSs. Each Offered ADS will initially represent the right to receive [●] Ordinary Share deposited with the Depositary pursuant to the Deposit Agreement.
VTEX Class A common shares, par value US$[•] per share Underwriting AgreementUnderwriting Agreement • July 12th, 2021 • Vtex • Services-prepackaged software • New York
VTEX, an exempted company incorporated under the laws of the Cayman Islands with limited liability (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] Class A common shares, par value US$0.0001 per share, of the Company and, certain shareholders of the Company listed in Schedule 2 hereto (the “Selling Shareholders”) propose to sell to the Underwriters an aggregate of [•] Class A common shares, par value US$0.0001 per share of the Company (collectively, the “Underwritten Shares”). In addition, at the option of the Underwriters, the Company proposes to sell to the Underwriters up to an additional [•] Class A common shares par value US$0.0001 per share, of the Company (collectively, the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The Class A common shares, par value US$0.000
UNDERWRITING AGREEMENT Aligos Therapeutics, Inc. [•] Shares of Common StockUnderwriting Agreement • June 28th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
KRISPY KREME, INC. [•] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 25th, 2021 • Krispy Kreme, Inc. • Retail-food stores • New York
Krispy Kreme, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.01 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT CVRx, Inc. [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 23rd, 2021 • CVRx, Inc. • Surgical & medical instruments & apparatus • New York
CVRx, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT ELEVATION ONCOLOGY, INC. [l] Shares of Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • June 21st, 2021 • Elevation Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Elevation Oncology, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [l] shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [l] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT VERVE THERAPEUTICS, INC. [●] Shares of Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • June 14th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
Verve Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
